What is NRXS's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.09B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for NRXS?

P/E (TTM) is n/a and 52-week range is $2.21 to $9.33 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s NRXS figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for NRXS?

The company profile lists revenue (TTM) near $5M, net income (TTM) near $-784M, EPS (TTM) near $-0.71 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Neuraxis Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Carmel, Indiana, US, 12.4M shares outstanding, ISIN US64134X2018 when available from company profile and filing metadata.

Neuraxis Inc

$NRXS

Health Care · Health Care Equipment & Supplies

IR Run Scenarios

$6.93

+2.36%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

NeurAxis, Inc. engages in the provision of neuromodulation therapies to address chronic and debilitating conditions in children. The company is headquartered in Carmel, Indiana and currently employs 24 full-time employees. The company went IPO on 2023-08-09. The firm is focused on developing neuromodulation therapies for chronic and debilitating conditions in gastrointestinal (GI) digestive system, specifically from disorders of the gut-brain interaction (DGBIs) in pediatrics and adults. Its IB-Stim, is a Percutaneous Electrical Nerve Field Stimulation (PENFS) technology intended to be used in patients eight years and older with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms. Its second product, RED (Rectal Expulsion Device), is indicated to evaluate the neuromuscular function of a patient’s ability to expel its contents from the rectum and as a qualitative test for rectal hypersensitivity. RED (K242304, 2024) helps identify patients with rectal hypersensitivity who experience a desire or urge to defecate at lower volumes of distension.

Employees

Website

neuraxis.com/

IPO

2023-08-09

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)